Anika Therapeutics (ANIK) Projected to Release Earnings on Wednesday

Anika Therapeutics (NASDAQ:ANIK) is expected to be announcing its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect Anika Therapeutics to announce earnings of $0.03 per share and revenue of $29.2140 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:30 AM ET.

Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.34. The firm had revenue of $29.61 million for the quarter, compared to analysts’ expectations of $28.14 million. Anika Therapeutics had a negative return on equity of 5.90% and a negative net margin of 9.52%. On average, analysts expect Anika Therapeutics to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Anika Therapeutics Trading Up 0.7%

Shares of ANIK opened at $15.16 on Wednesday. The business’s 50-day moving average price is $14.99 and its 200 day moving average price is $13.42. The stock has a market capitalization of $201.78 million, a P/E ratio of -19.19 and a beta of 0.23. Anika Therapeutics has a 1-year low of $7.87 and a 1-year high of $16.49.

Insider Buying and Selling at Anika Therapeutics

In other Anika Therapeutics news, CEO Stephen D. Griffin bought 12,200 shares of the firm’s stock in a transaction dated Thursday, April 30th. The stock was acquired at an average price of $12.29 per share, with a total value of $149,938.00. Following the completion of the transaction, the chief executive officer directly owned 36,163 shares in the company, valued at approximately $444,443.27. This represents a 50.91% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director John B. Henneman III purchased 5,000 shares of the stock in a transaction dated Friday, May 1st. The shares were acquired at an average price of $14.66 per share, for a total transaction of $73,300.00. Following the acquisition, the director directly owned 54,871 shares of the company’s stock, valued at $804,408.86. This represents a 10.03% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 12.08% of the company’s stock.

Institutional Investors Weigh In On Anika Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Quarry LP purchased a new position in Anika Therapeutics during the 3rd quarter valued at about $71,000. Occudo Quantitative Strategies LP purchased a new stake in shares of Anika Therapeutics in the third quarter worth approximately $95,000. Ieq Capital LLC purchased a new stake in shares of Anika Therapeutics in the fourth quarter worth approximately $97,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Anika Therapeutics during the fourth quarter worth approximately $122,000. Finally, Jain Global LLC acquired a new stake in shares of Anika Therapeutics during the fourth quarter worth approximately $137,000. 91.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anika Therapeutics in a report on Wednesday, June 24th. Wall Street Zen lowered shares of Anika Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Anika Therapeutics presently has a consensus rating of “Hold” and an average target price of $17.00.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.

The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.